Asset Management One Co. Ltd. Buys 2,336 Shares of Edwards Lifesciences Corporation $EW

Asset Management One Co. Ltd. increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 0.9% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 252,425 shares of the medical research company’s stock after purchasing an additional 2,336 shares during the quarter. Asset Management One Co. Ltd.’s holdings in Edwards Lifesciences were worth $19,742,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Quantbot Technologies LP purchased a new stake in Edwards Lifesciences in the 1st quarter valued at $26,000. SouthState Corp purchased a new stake in Edwards Lifesciences in the first quarter worth about $27,000. Rosenberg Matthew Hamilton bought a new position in Edwards Lifesciences during the second quarter valued at approximately $28,000. Tradewinds Capital Management LLC raised its holdings in shares of Edwards Lifesciences by 102.5% in the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock worth $29,000 after buying an additional 205 shares during the period. Finally, Rossby Financial LCC purchased a new position in shares of Edwards Lifesciences in the 1st quarter valued at $29,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 4,114 shares of the business’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president owned 22,002 shares of the company’s stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider directly owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Down 0.5%

Shares of EW opened at $76.15 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The business has a 50-day moving average of $77.37 and a 200 day moving average of $76.43. The firm has a market cap of $44.70 billion, a P/E ratio of 10.96, a price-to-earnings-growth ratio of 3.65 and a beta of 1.05. Edwards Lifesciences Corporation has a fifty-two week low of $64.89 and a fifty-two week high of $83.00.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company’s quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.70 earnings per share. As a group, research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on EW shares. Wall Street Zen lowered Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 29th. Piper Sandler lifted their price target on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, July 25th. JPMorgan Chase & Co. boosted their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday, July 25th. The Goldman Sachs Group reiterated a “buy” rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Finally, Argus upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a research note on Thursday, July 10th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus price target of $87.06.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.